Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.

Get EBS alerts

About Rich Lindahl

Rich Lindahl is recorded as CFO at Emergent BioSolutions Inc. (EBS). Rich Lindahl has spoken on 26 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on August 5, 2026. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.

Rich Lindahl on recent calls

“We delivered a strong second quarter and first half of 2026, with revenue and adjusted EBITDA exceeding both our internal expectations and the analyst consensus.”
CFO, Q2 2026 Emergent BioSolutions Inc. Earnings Conference Call ·
“We started fiscal year 2026 with a strong first quarter, with revenue exceeding the top end of our guidance. We've also advanced key strategic priorities and improved our cash and liquidity position versus the prior year.”
CFO, Emergent BioSolutions Inc. Q1 FY2026 Earnings Call ·
“We're excited to share the strong progress we made in 2025 and the continued momentum we're carrying into 2020 since. 2025 was a year of meaningful advancement for Emergent, one where our transition from stabilization to turnaround gained real traction.”
CFO, Emergent BioSolutions Inc. Q4 FY2025 Earnings Call ·
“As Joe has just highlighted, we are off to a strong start in 2025 as we continue to make progress on our multiyear transformation plan. We delivered first quarter revenue in line with our guidance, enhanced our cash position and reduced our net leverage ratio.”
CFO, Emergent BioSolutions Inc. Q1 FY2025 Earnings Call ·
“As Joe has just discussed coming out of the third quarter, our significant progress against our operational and financial priorities is enabling us to transition from the stabilization phase to the turnaround phase.”
CFO, Emergent BioSolutions Inc. Q3 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Emergent BioSolutions Inc.

Recent activity

Show 14 earlier activities